Datasets:
| { | |
| "benchmark_id": "34857732_01", | |
| "sample_system": "", | |
| "tissue": "Prostate", | |
| "source_type": "cell_line", | |
| "perturbation_type": "drug", | |
| "perturbation_name": "GSK126", | |
| "default_cell_subset": "", | |
| "description": "LNCaP prostate cancer cells treated with EZH2 inhibitor GSK126.", | |
| "smiles": "CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C", | |
| "test_cases": [ | |
| { | |
| "test_id": "34857732_01_01", | |
| "target_genes": [ | |
| "UBE2C", | |
| "CDK1" | |
| ], | |
| "perturb_var": "dose", | |
| "control": "C", | |
| "dose_groups": [ | |
| "1.0 uM" | |
| ], | |
| "time_groups": [], | |
| "relation": "DOWN", | |
| "cell_type": "LNCaP prostate cancer cell line" | |
| }, | |
| { | |
| "test_id": "34857732_01_02", | |
| "target_genes": [ | |
| "KLK3", | |
| "TMPRSS2", | |
| "KLK2", | |
| "ABCC4" | |
| ], | |
| "perturb_var": "dose", | |
| "control": "C", | |
| "dose_groups": [ | |
| "1.0 uM" | |
| ], | |
| "time_groups": [], | |
| "relation": "UP", | |
| "cell_type": "LNCaP prostate cancer cell line" | |
| }, | |
| { | |
| "test_id": "34857732_01_03", | |
| "target_genes": [ | |
| "IL13", | |
| "IL4" | |
| ], | |
| "perturb_var": "dose", | |
| "control": "C", | |
| "dose_groups": [ | |
| "1.0 uM" | |
| ], | |
| "time_groups": [], | |
| "relation": "NS", | |
| "cell_type": "LNCaP prostate cancer cell line" | |
| } | |
| ] | |
| } |